# Atigotatug

Source: https://onco.cc/drugs/atigotatug/  
OnCo record `atigotatug` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Atigotatug is an experimental monoclonal antibody from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

Atigotatug (BMS-986489) is a monoclonal antibody developed by Bristol-Myers Squibb. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)), in non-small-cell lung cancer. The largest, NCT06646276, plans to enrol 530 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: BMS-986489 (Atigotatug
- Tags: pipeline; ctgov-ingest
- Code: BMS-986489
- Modality: monoclonal antibody
- Mechanism: Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab.

## Sources

- ClinicalTrials.gov: trials of Atigotatug: https://clinicaltrials.gov/search?intr=Atigotatug
- Sponsor pipeline page: https://www.bms.com/researchers-and-partners/in-the-pipeline.html

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)](https://onco.cc/trials/nct06646276/)

---
JSON: https://onco.cc/api/v1/entities/atigotatug.json